Nirmatrelvir/Ritonavir Is Safe For High-Risk Children With COVID-19, Study Suggests

Infectious Disease Advisor (1/22, Kuhns) reports, “Nirmatrelvir/ritonavir (Paxlovid) is safe for high-risk children with COVID-19 and may offer marginal benefits for low-risk children with COVID-19, according to study findings.” The researchers said, “Larger pediatric studies are needed to clarify causal relationships and assess clinical outcomes more accurately.” The findings were published in The Pediatric Infectious Disease Journal.